Global Membranous Nephropathy Market

Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceutical), Test Type (Urine & Blood Test, Kidney Biopsy, Glomerular Filtration Rate (GFR)) Players and Region - Global Market Outlook to 2030

Membranous Nephropathy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Membranous Nephropathy Market Overview:
Membranous Nephropathy is a type of kidney disorder that is caused by thickening part of the glomerular basement membrane. The disease is most commonly found in adults with age of more than 40, however very less in children. Patient with kidney disease has been increasing due to change in lifestyle and eating habits of people. Most of the global population with membranous nephropathy has primary conditions that may lead manufacturers for research & development of drugs or therapies for idiopathic membranous nephropathy. However, growing preference towards the therapies that avoid requirement of surgeries or invasive procedures may create significant opportunities for market.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Emerging Trend of Biologics Therapies As An Effective Treatment Option Boost The Market and Demand for Technologically Advanced Treatment Options Such as Laser Microdissection

Market Growth Drivers:
Rising Number of People with Kidney Disease Due to Changing Lifestyle and Baby Boomers and Demand of Drugs for Membranous Nephropathy Therapy to Avoid Surgery or Other Invasive Procedure

Challenges:
Limited Availability of Treatments and High Cost May Create Restraints

Restraints:
Regulatory Requirements and Reimbursement Policies for Drug Development and Approval May Affect the Growth

Opportunities:
Number of People With Primary membranous Nephropathy Across the Globe May Create Significant Opportunities for Market

Competitive Landscape:
Global market consists limited number of players and focusing on business strategies such as acquisition, partnership, new product launch, etc. in order to expand its portfolio or geographical footprint. The key players are probable to keep a stronghold on the market over the anticipated period.
Some of the key players profiled in the report are AstraZeneca (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), GSK plc (United Kingdom), Takeda Pharmaceuticals (Japan), Novartis AG (Switzerland), Cerium Pharmaceuticals, Inc. (United States), EUROIMMUN Medizinische Labordiagnostika AG (Germany) and Biogen (United States). Analyst at AMA Research see European Players to retain maximum share of Global Membranous Nephropathy market by 2030. Considering Market by Age Group, the sub-segment i.e. Children will boost the Membranous Nephropathy market. Considering Market by Treatment Type, the sub-segment i.e. Biologics will boost the Membranous Nephropathy market. Considering Market by Test Type, the sub-segment i.e. Urine & Blood Test will boost the Membranous Nephropathy market.

In May 2024, Biogen acquired Human Immunology Biosciences to expand its Immunology Portfolio. The transaction includes felzartamab as well as other immunology drug portfolio. Felzartamab has received orphan drug designation and breakthrough therapy designation from USFDA to treat primary membranous nephropathy (PMN) antibody-mediated rejection (AMR).

What Can be Explored with the Membranous Nephropathy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Membranous Nephropathy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Membranous Nephropathy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Membranous Nephropathy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Membranous Nephropathy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Membranous Nephropathy Drug Manufacturers, Test or Diagnostic Solution & service Providers, Government Regulatory and Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Primary Membranous Nephropathy (Idiopathic)
  • Secondary Membranous Nephropathy
By Age Group
  • Children
  • Adults

By Treatment Type
  • Biologics
  • Pharmaceutical

By Test Type
  • Urine & Blood Test
  • Kidney Biopsy
  • Glomerular Filtration Rate (GFR)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of People with Kidney Disease Due to Changing Lifestyle and Baby Boomers
      • 3.2.2. Demand of Drugs for Membranous Nephropathy Therapy to Avoid Surgery or Other Invasive Procedure
    • 3.3. Market Challenges
      • 3.3.1. Limited Availability of Treatments and High Cost May Create Restraints
    • 3.4. Market Trends
      • 3.4.1. Emerging Trend of Biologics Therapies As An Effective Treatment Option Boost The Market
      • 3.4.2. Demand for Technologically Advanced Treatment Options Such as Laser Microdissection
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Membranous Nephropathy, by Type, Age Group, Treatment Type, Test Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Membranous Nephropathy (Value)
      • 5.2.1. Global Membranous Nephropathy by: Type (Value)
        • 5.2.1.1. Primary Membranous Nephropathy (Idiopathic)
        • 5.2.1.2. Secondary Membranous Nephropathy
      • 5.2.2. Global Membranous Nephropathy by: Age Group (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Membranous Nephropathy by: Treatment Type (Value)
        • 5.2.3.1. Biologics
        • 5.2.3.2. Pharmaceutical
      • 5.2.4. Global Membranous Nephropathy by: Test Type (Value)
        • 5.2.4.1. Urine & Blood Test
        • 5.2.4.2. Kidney Biopsy
        • 5.2.4.3. Glomerular Filtration Rate (GFR)
      • 5.2.5. Global Membranous Nephropathy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Membranous Nephropathy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GSK plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceuticals (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cerium Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. EUROIMMUN Medizinische Labordiagnostika AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Membranous Nephropathy Sale, by Type, Age Group, Treatment Type, Test Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Membranous Nephropathy (Value)
      • 7.2.1. Global Membranous Nephropathy by: Type (Value)
        • 7.2.1.1. Primary Membranous Nephropathy (Idiopathic)
        • 7.2.1.2. Secondary Membranous Nephropathy
      • 7.2.2. Global Membranous Nephropathy by: Age Group (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Membranous Nephropathy by: Treatment Type (Value)
        • 7.2.3.1. Biologics
        • 7.2.3.2. Pharmaceutical
      • 7.2.4. Global Membranous Nephropathy by: Test Type (Value)
        • 7.2.4.1. Urine & Blood Test
        • 7.2.4.2. Kidney Biopsy
        • 7.2.4.3. Glomerular Filtration Rate (GFR)
      • 7.2.5. Global Membranous Nephropathy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Membranous Nephropathy: by Type(USD Million)
  • Table 2. Membranous Nephropathy Primary Membranous Nephropathy (Idiopathic) , by Region USD Million (2018-2023)
  • Table 3. Membranous Nephropathy Secondary Membranous Nephropathy , by Region USD Million (2018-2023)
  • Table 4. Membranous Nephropathy: by Age Group(USD Million)
  • Table 5. Membranous Nephropathy Children , by Region USD Million (2018-2023)
  • Table 6. Membranous Nephropathy Adults , by Region USD Million (2018-2023)
  • Table 7. Membranous Nephropathy: by Treatment Type(USD Million)
  • Table 8. Membranous Nephropathy Biologics , by Region USD Million (2018-2023)
  • Table 9. Membranous Nephropathy Pharmaceutical , by Region USD Million (2018-2023)
  • Table 10. Membranous Nephropathy: by Test Type(USD Million)
  • Table 11. Membranous Nephropathy Urine & Blood Test , by Region USD Million (2018-2023)
  • Table 12. Membranous Nephropathy Kidney Biopsy , by Region USD Million (2018-2023)
  • Table 13. Membranous Nephropathy Glomerular Filtration Rate (GFR) , by Region USD Million (2018-2023)
  • Table 14. South America Membranous Nephropathy, by Country USD Million (2018-2023)
  • Table 15. South America Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 16. South America Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 17. South America Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 18. South America Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 19. Brazil Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 20. Brazil Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 21. Brazil Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 22. Brazil Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 23. Argentina Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 24. Argentina Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 25. Argentina Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 26. Argentina Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 27. Rest of South America Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 29. Rest of South America Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 30. Rest of South America Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 31. Asia Pacific Membranous Nephropathy, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 34. Asia Pacific Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 35. Asia Pacific Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 36. China Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 37. China Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 38. China Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 39. China Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 40. Japan Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 41. Japan Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 42. Japan Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 43. Japan Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 44. India Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 45. India Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 46. India Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 47. India Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 48. South Korea Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 49. South Korea Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 50. South Korea Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 51. South Korea Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 52. Taiwan Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 53. Taiwan Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 54. Taiwan Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 55. Taiwan Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 56. Australia Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 57. Australia Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 58. Australia Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 59. Australia Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 64. Europe Membranous Nephropathy, by Country USD Million (2018-2023)
  • Table 65. Europe Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 66. Europe Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 67. Europe Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 68. Europe Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 69. Germany Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 70. Germany Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 71. Germany Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 72. Germany Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 73. France Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 74. France Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 75. France Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 76. France Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 77. Italy Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 78. Italy Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 79. Italy Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 80. Italy Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 81. United Kingdom Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 83. United Kingdom Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 84. United Kingdom Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 85. Netherlands Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 86. Netherlands Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 87. Netherlands Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 88. Netherlands Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 89. Rest of Europe Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 91. Rest of Europe Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 92. Rest of Europe Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 93. MEA Membranous Nephropathy, by Country USD Million (2018-2023)
  • Table 94. MEA Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 95. MEA Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 96. MEA Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 97. MEA Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 98. Middle East Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 99. Middle East Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 100. Middle East Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 101. Middle East Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 102. Africa Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 103. Africa Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 104. Africa Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 105. Africa Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 106. North America Membranous Nephropathy, by Country USD Million (2018-2023)
  • Table 107. North America Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 108. North America Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 109. North America Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 110. North America Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 111. United States Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 112. United States Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 113. United States Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 114. United States Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 115. Canada Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 116. Canada Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 117. Canada Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 118. Canada Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 119. Mexico Membranous Nephropathy, by Type USD Million (2018-2023)
  • Table 120. Mexico Membranous Nephropathy, by Age Group USD Million (2018-2023)
  • Table 121. Mexico Membranous Nephropathy, by Treatment Type USD Million (2018-2023)
  • Table 122. Mexico Membranous Nephropathy, by Test Type USD Million (2018-2023)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Membranous Nephropathy: by Type(USD Million)
  • Table 132. Membranous Nephropathy Primary Membranous Nephropathy (Idiopathic) , by Region USD Million (2025-2030)
  • Table 133. Membranous Nephropathy Secondary Membranous Nephropathy , by Region USD Million (2025-2030)
  • Table 134. Membranous Nephropathy: by Age Group(USD Million)
  • Table 135. Membranous Nephropathy Children , by Region USD Million (2025-2030)
  • Table 136. Membranous Nephropathy Adults , by Region USD Million (2025-2030)
  • Table 137. Membranous Nephropathy: by Treatment Type(USD Million)
  • Table 138. Membranous Nephropathy Biologics , by Region USD Million (2025-2030)
  • Table 139. Membranous Nephropathy Pharmaceutical , by Region USD Million (2025-2030)
  • Table 140. Membranous Nephropathy: by Test Type(USD Million)
  • Table 141. Membranous Nephropathy Urine & Blood Test , by Region USD Million (2025-2030)
  • Table 142. Membranous Nephropathy Kidney Biopsy , by Region USD Million (2025-2030)
  • Table 143. Membranous Nephropathy Glomerular Filtration Rate (GFR) , by Region USD Million (2025-2030)
  • Table 144. South America Membranous Nephropathy, by Country USD Million (2025-2030)
  • Table 145. South America Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 146. South America Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 147. South America Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 148. South America Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 149. Brazil Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 150. Brazil Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 151. Brazil Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 152. Brazil Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 153. Argentina Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 154. Argentina Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 155. Argentina Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 156. Argentina Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 157. Rest of South America Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 158. Rest of South America Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 159. Rest of South America Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 160. Rest of South America Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 161. Asia Pacific Membranous Nephropathy, by Country USD Million (2025-2030)
  • Table 162. Asia Pacific Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 163. Asia Pacific Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 164. Asia Pacific Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 165. Asia Pacific Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 166. China Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 167. China Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 168. China Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 169. China Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 170. Japan Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 171. Japan Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 172. Japan Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 173. Japan Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 174. India Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 175. India Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 176. India Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 177. India Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 178. South Korea Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 179. South Korea Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 180. South Korea Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 181. South Korea Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 182. Taiwan Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 183. Taiwan Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 184. Taiwan Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 185. Taiwan Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 186. Australia Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 187. Australia Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 188. Australia Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 189. Australia Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 190. Rest of Asia-Pacific Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 191. Rest of Asia-Pacific Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 194. Europe Membranous Nephropathy, by Country USD Million (2025-2030)
  • Table 195. Europe Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 196. Europe Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 197. Europe Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 198. Europe Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 199. Germany Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 200. Germany Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 201. Germany Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 202. Germany Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 203. France Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 204. France Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 205. France Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 206. France Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 207. Italy Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 208. Italy Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 209. Italy Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 210. Italy Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 211. United Kingdom Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 212. United Kingdom Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 213. United Kingdom Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 214. United Kingdom Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 215. Netherlands Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 216. Netherlands Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 217. Netherlands Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 218. Netherlands Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 219. Rest of Europe Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 220. Rest of Europe Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 221. Rest of Europe Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 222. Rest of Europe Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 223. MEA Membranous Nephropathy, by Country USD Million (2025-2030)
  • Table 224. MEA Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 225. MEA Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 226. MEA Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 227. MEA Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 228. Middle East Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 229. Middle East Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 230. Middle East Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 231. Middle East Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 232. Africa Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 233. Africa Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 234. Africa Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 235. Africa Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 236. North America Membranous Nephropathy, by Country USD Million (2025-2030)
  • Table 237. North America Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 238. North America Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 239. North America Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 240. North America Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 241. United States Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 242. United States Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 243. United States Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 244. United States Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 245. Canada Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 246. Canada Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 247. Canada Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 248. Canada Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 249. Mexico Membranous Nephropathy, by Type USD Million (2025-2030)
  • Table 250. Mexico Membranous Nephropathy, by Age Group USD Million (2025-2030)
  • Table 251. Mexico Membranous Nephropathy, by Treatment Type USD Million (2025-2030)
  • Table 252. Mexico Membranous Nephropathy, by Test Type USD Million (2025-2030)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Membranous Nephropathy: by Type USD Million (2018-2023)
  • Figure 5. Global Membranous Nephropathy: by Age Group USD Million (2018-2023)
  • Figure 6. Global Membranous Nephropathy: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Membranous Nephropathy: by Test Type USD Million (2018-2023)
  • Figure 8. South America Membranous Nephropathy Share (%), by Country
  • Figure 9. Asia Pacific Membranous Nephropathy Share (%), by Country
  • Figure 10. Europe Membranous Nephropathy Share (%), by Country
  • Figure 11. MEA Membranous Nephropathy Share (%), by Country
  • Figure 12. North America Membranous Nephropathy Share (%), by Country
  • Figure 13. Global Membranous Nephropathy share by Players 2023 (%)
  • Figure 14. Global Membranous Nephropathy share by Players (Top 3) 2023(%)
  • Figure 15. Global Membranous Nephropathy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GSK plc (United Kingdom) Revenue: by Geography 2023
  • Figure 23. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Cerium Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cerium Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. EUROIMMUN Medizinische Labordiagnostika AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. EUROIMMUN Medizinische Labordiagnostika AG (Germany) Revenue: by Geography 2023
  • Figure 31. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 32. Biogen (United States) Revenue: by Geography 2023
  • Figure 33. Global Membranous Nephropathy: by Type USD Million (2025-2030)
  • Figure 34. Global Membranous Nephropathy: by Age Group USD Million (2025-2030)
  • Figure 35. Global Membranous Nephropathy: by Treatment Type USD Million (2025-2030)
  • Figure 36. Global Membranous Nephropathy: by Test Type USD Million (2025-2030)
  • Figure 37. South America Membranous Nephropathy Share (%), by Country
  • Figure 38. Asia Pacific Membranous Nephropathy Share (%), by Country
  • Figure 39. Europe Membranous Nephropathy Share (%), by Country
  • Figure 40. MEA Membranous Nephropathy Share (%), by Country
  • Figure 41. North America Membranous Nephropathy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GSK plc (United Kingdom)
  • Takeda Pharmaceuticals (Japan)
  • Novartis AG (Switzerland)
  • Cerium Pharmaceuticals, Inc. (United States)
  • EUROIMMUN Medizinische Labordiagnostika AG (Germany)
  • Biogen (United States)
Select User Access Type

Key Highlights of Report


Jun 2024 209 Pages 69 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Membranous Nephropathy Market Quantitative research analysis
Global Membranous Nephropathy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Membranous Nephropathy market are AstraZeneca (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), GSK plc (United Kingdom), Takeda Pharmaceuticals (Japan), Novartis AG (Switzerland), Cerium Pharmaceuticals, Inc. (United States), EUROIMMUN Medizinische Labordiagnostika AG (Germany) and Biogen (United States), to name a few.
"Emerging Trend of Biologics Therapies As An Effective Treatment Option Boost The Market " is seen as one of major influencing trends for Membranous Nephropathy Market during projected period 2023-2030.
Primary Membranous Nephropathy (Idiopathic) segment in Global market to hold robust market share owing to "Rising Number of People with Kidney Disease Due to Changing Lifestyle and Baby Boomers ".

Know More About Global Membranous Nephropathy Market Report?

Have a Query? Click Here

Other Related Reports

Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
$ 3800
Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Co...
$ 3800